CN107028149A - 一种富铁保健盐及其制备方法 - Google Patents
一种富铁保健盐及其制备方法 Download PDFInfo
- Publication number
- CN107028149A CN107028149A CN201710255873.0A CN201710255873A CN107028149A CN 107028149 A CN107028149 A CN 107028149A CN 201710255873 A CN201710255873 A CN 201710255873A CN 107028149 A CN107028149 A CN 107028149A
- Authority
- CN
- China
- Prior art keywords
- rich iron
- health
- ferrous
- salt
- care salt
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- XEEYBQQBJWHFJM-UHFFFAOYSA-N Iron Chemical compound [Fe] XEEYBQQBJWHFJM-UHFFFAOYSA-N 0.000 title claims abstract description 115
- 150000003839 salts Chemical class 0.000 title claims abstract description 82
- 229910052742 iron Inorganic materials 0.000 title claims abstract description 56
- 238000002360 preparation method Methods 0.000 title claims abstract description 15
- 235000002639 sodium chloride Nutrition 0.000 claims abstract description 103
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 claims abstract description 43
- CIWBSHSKHKDKBQ-JLAZNSOCSA-N Ascorbic acid Chemical compound OC[C@H](O)[C@H]1OC(=O)C(O)=C1O CIWBSHSKHKDKBQ-JLAZNSOCSA-N 0.000 claims abstract description 32
- WCUXLLCKKVVCTQ-UHFFFAOYSA-M Potassium chloride Chemical compound [Cl-].[K+] WCUXLLCKKVVCTQ-UHFFFAOYSA-M 0.000 claims abstract description 30
- 239000000843 powder Substances 0.000 claims abstract description 24
- 239000011780 sodium chloride Substances 0.000 claims abstract description 24
- 244000068988 Glycine max Species 0.000 claims abstract description 18
- 235000010469 Glycine max Nutrition 0.000 claims abstract description 17
- 240000004922 Vigna radiata Species 0.000 claims abstract description 17
- 229910000359 iron(II) sulfate Inorganic materials 0.000 claims abstract description 17
- 235000010721 Vigna radiata var radiata Nutrition 0.000 claims abstract description 16
- 235000011469 Vigna radiata var sublobata Nutrition 0.000 claims abstract description 16
- BAUYGSIQEAFULO-UHFFFAOYSA-L iron(2+) sulfate (anhydrous) Chemical compound [Fe+2].[O-]S([O-])(=O)=O BAUYGSIQEAFULO-UHFFFAOYSA-L 0.000 claims abstract description 16
- DKKCQDROTDCQOR-UHFFFAOYSA-L Ferrous lactate Chemical compound [Fe+2].CC(O)C([O-])=O.CC(O)C([O-])=O DKKCQDROTDCQOR-UHFFFAOYSA-L 0.000 claims abstract description 15
- 235000013925 ferrous lactate Nutrition 0.000 claims abstract description 15
- 239000004225 ferrous lactate Substances 0.000 claims abstract description 15
- 229940037907 ferrous lactate Drugs 0.000 claims abstract description 15
- 239000011790 ferrous sulphate Substances 0.000 claims abstract description 15
- 235000003891 ferrous sulphate Nutrition 0.000 claims abstract description 15
- 239000001103 potassium chloride Substances 0.000 claims abstract description 15
- 235000011164 potassium chloride Nutrition 0.000 claims abstract description 15
- 235000010323 ascorbic acid Nutrition 0.000 claims abstract description 14
- 229960005070 ascorbic acid Drugs 0.000 claims abstract description 14
- 239000011668 ascorbic acid Substances 0.000 claims abstract description 14
- 235000013924 ferrous gluconate Nutrition 0.000 claims abstract description 14
- 239000004222 ferrous gluconate Substances 0.000 claims abstract description 14
- 229960001645 ferrous gluconate Drugs 0.000 claims abstract description 14
- 235000013312 flour Nutrition 0.000 claims abstract description 14
- VRIVJOXICYMTAG-IYEMJOQQSA-L iron(ii) gluconate Chemical compound [Fe+2].OC[C@@H](O)[C@@H](O)[C@H](O)[C@@H](O)C([O-])=O.OC[C@@H](O)[C@@H](O)[C@H](O)[C@@H](O)C([O-])=O VRIVJOXICYMTAG-IYEMJOQQSA-L 0.000 claims abstract description 14
- FAPWYRCQGJNNSJ-UBKPKTQASA-L calcium D-pantothenic acid Chemical compound [Ca+2].OCC(C)(C)[C@@H](O)C(=O)NCCC([O-])=O.OCC(C)(C)[C@@H](O)C(=O)NCCC([O-])=O FAPWYRCQGJNNSJ-UBKPKTQASA-L 0.000 claims abstract description 13
- 239000001506 calcium phosphate Substances 0.000 claims abstract description 12
- 229910000389 calcium phosphate Inorganic materials 0.000 claims abstract description 12
- 235000011010 calcium phosphates Nutrition 0.000 claims abstract description 12
- QORWJWZARLRLPR-UHFFFAOYSA-H tricalcium bis(phosphate) Chemical compound [Ca+2].[Ca+2].[Ca+2].[O-]P([O-])([O-])=O.[O-]P([O-])([O-])=O QORWJWZARLRLPR-UHFFFAOYSA-H 0.000 claims abstract description 12
- 229960002079 calcium pantothenate Drugs 0.000 claims abstract description 10
- 229960001781 ferrous sulfate Drugs 0.000 claims abstract description 6
- 229960002816 potassium chloride Drugs 0.000 claims abstract description 5
- 229960001714 calcium phosphate Drugs 0.000 claims abstract description 3
- 229960002668 sodium chloride Drugs 0.000 claims abstract description 3
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 claims description 24
- OYPRJOBELJOOCE-UHFFFAOYSA-N Calcium Chemical compound [Ca] OYPRJOBELJOOCE-UHFFFAOYSA-N 0.000 claims description 12
- 235000001465 calcium Nutrition 0.000 claims description 12
- 239000011575 calcium Substances 0.000 claims description 12
- 229910052791 calcium Inorganic materials 0.000 claims description 12
- 239000000693 micelle Substances 0.000 claims description 7
- 239000000463 material Substances 0.000 claims description 5
- 238000002604 ultrasonography Methods 0.000 claims description 5
- 238000002242 deionisation method Methods 0.000 claims description 4
- 238000000034 method Methods 0.000 claims description 4
- 229940076638 ascorbic acid and calcium Drugs 0.000 claims description 3
- 229920002338 polyhydroxyethylmethacrylate Polymers 0.000 claims description 3
- 238000009777 vacuum freeze-drying Methods 0.000 claims description 2
- 230000005415 magnetization Effects 0.000 claims 1
- 230000036772 blood pressure Effects 0.000 abstract description 14
- 210000004369 blood Anatomy 0.000 abstract description 12
- 239000008280 blood Substances 0.000 abstract description 12
- 239000003814 drug Substances 0.000 abstract description 10
- DGAQECJNVWCQMB-PUAWFVPOSA-M Ilexoside XXIX Chemical compound C[C@@H]1CC[C@@]2(CC[C@@]3(C(=CC[C@H]4[C@]3(CC[C@@H]5[C@@]4(CC[C@@H](C5(C)C)OS(=O)(=O)[O-])C)C)[C@@H]2[C@]1(C)O)C)C(=O)O[C@H]6[C@@H]([C@H]([C@@H]([C@H](O6)CO)O)O)O.[Na+] DGAQECJNVWCQMB-PUAWFVPOSA-M 0.000 abstract description 7
- 235000011194 food seasoning agent Nutrition 0.000 abstract description 7
- 239000011734 sodium Substances 0.000 abstract description 7
- 229910052708 sodium Inorganic materials 0.000 abstract description 7
- 230000036541 health Effects 0.000 abstract description 6
- 230000000157 blood function Effects 0.000 abstract description 3
- 230000000694 effects Effects 0.000 description 14
- 208000007502 anemia Diseases 0.000 description 11
- 235000013305 food Nutrition 0.000 description 9
- 206010020772 Hypertension Diseases 0.000 description 8
- 239000000047 product Substances 0.000 description 8
- ZLMJMSJWJFRBEC-UHFFFAOYSA-N Potassium Chemical compound [K] ZLMJMSJWJFRBEC-UHFFFAOYSA-N 0.000 description 7
- 239000003795 chemical substances by application Substances 0.000 description 7
- 239000011591 potassium Substances 0.000 description 7
- 229910052700 potassium Inorganic materials 0.000 description 7
- HVYWMOMLDIMFJA-DPAQBDIFSA-N cholesterol Chemical compound C1C=C2C[C@@H](O)CC[C@]2(C)[C@@H]2[C@@H]1[C@@H]1CC[C@H]([C@H](C)CCCC(C)C)[C@@]1(C)CC2 HVYWMOMLDIMFJA-DPAQBDIFSA-N 0.000 description 6
- 239000000796 flavoring agent Substances 0.000 description 6
- 235000019634 flavors Nutrition 0.000 description 6
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 5
- 238000010521 absorption reaction Methods 0.000 description 5
- 230000008901 benefit Effects 0.000 description 5
- 229940079593 drug Drugs 0.000 description 5
- 210000003743 erythrocyte Anatomy 0.000 description 5
- PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerine Chemical compound OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 description 4
- 102000001554 Hemoglobins Human genes 0.000 description 4
- 108010054147 Hemoglobins Proteins 0.000 description 4
- HCHKCACWOHOZIP-UHFFFAOYSA-N Zinc Chemical compound [Zn] HCHKCACWOHOZIP-UHFFFAOYSA-N 0.000 description 4
- 230000035488 systolic blood pressure Effects 0.000 description 4
- 239000011701 zinc Substances 0.000 description 4
- 229910052725 zinc Inorganic materials 0.000 description 4
- 206010006956 Calcium deficiency Diseases 0.000 description 3
- OAICVXFJPJFONN-UHFFFAOYSA-N Phosphorus Chemical compound [P] OAICVXFJPJFONN-UHFFFAOYSA-N 0.000 description 3
- FKNQFGJONOIPTF-UHFFFAOYSA-N Sodium cation Chemical compound [Na+] FKNQFGJONOIPTF-UHFFFAOYSA-N 0.000 description 3
- 235000012000 cholesterol Nutrition 0.000 description 3
- 239000000470 constituent Substances 0.000 description 3
- 201000010099 disease Diseases 0.000 description 3
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 3
- 238000001727 in vivo Methods 0.000 description 3
- 230000006698 induction Effects 0.000 description 3
- 229910052500 inorganic mineral Inorganic materials 0.000 description 3
- 210000002414 leg Anatomy 0.000 description 3
- 230000004060 metabolic process Effects 0.000 description 3
- 235000010755 mineral Nutrition 0.000 description 3
- 239000011707 mineral Substances 0.000 description 3
- 239000000203 mixture Substances 0.000 description 3
- 150000007524 organic acids Chemical class 0.000 description 3
- 239000002245 particle Substances 0.000 description 3
- 229910052698 phosphorus Inorganic materials 0.000 description 3
- 239000011574 phosphorus Substances 0.000 description 3
- BITYAPCSNKJESK-UHFFFAOYSA-N potassiosodium Chemical compound [Na].[K] BITYAPCSNKJESK-UHFFFAOYSA-N 0.000 description 3
- 239000000276 potassium ferrocyanide Substances 0.000 description 3
- 229910001415 sodium ion Inorganic materials 0.000 description 3
- 239000000126 substance Substances 0.000 description 3
- XOGGUFAVLNCTRS-UHFFFAOYSA-N tetrapotassium;iron(2+);hexacyanide Chemical compound [K+].[K+].[K+].[K+].[Fe+2].N#[C-].N#[C-].N#[C-].N#[C-].N#[C-].N#[C-] XOGGUFAVLNCTRS-UHFFFAOYSA-N 0.000 description 3
- 229940088594 vitamin Drugs 0.000 description 3
- 229930003231 vitamin Natural products 0.000 description 3
- 235000013343 vitamin Nutrition 0.000 description 3
- 239000011782 vitamin Substances 0.000 description 3
- 150000003722 vitamin derivatives Chemical class 0.000 description 3
- CURLTUGMZLYLDI-UHFFFAOYSA-N Carbon dioxide Chemical compound O=C=O CURLTUGMZLYLDI-UHFFFAOYSA-N 0.000 description 2
- HEDRZPFGACZZDS-UHFFFAOYSA-N Chloroform Chemical compound ClC(Cl)Cl HEDRZPFGACZZDS-UHFFFAOYSA-N 0.000 description 2
- ZZZCUOFIHGPKAK-UHFFFAOYSA-N D-erythro-ascorbic acid Natural products OCC1OC(=O)C(O)=C1O ZZZCUOFIHGPKAK-UHFFFAOYSA-N 0.000 description 2
- RTZKZFJDLAIYFH-UHFFFAOYSA-N Diethyl ether Chemical compound CCOCC RTZKZFJDLAIYFH-UHFFFAOYSA-N 0.000 description 2
- 206010020751 Hypersensitivity Diseases 0.000 description 2
- FYYHWMGAXLPEAU-UHFFFAOYSA-N Magnesium Chemical compound [Mg] FYYHWMGAXLPEAU-UHFFFAOYSA-N 0.000 description 2
- TWRXJAOTZQYOKJ-UHFFFAOYSA-L Magnesium chloride Chemical compound [Mg+2].[Cl-].[Cl-] TWRXJAOTZQYOKJ-UHFFFAOYSA-L 0.000 description 2
- 206010030113 Oedema Diseases 0.000 description 2
- 240000007594 Oryza sativa Species 0.000 description 2
- 235000007164 Oryza sativa Nutrition 0.000 description 2
- NBIIXXVUZAFLBC-UHFFFAOYSA-N Phosphoric acid Chemical compound OP(O)(O)=O NBIIXXVUZAFLBC-UHFFFAOYSA-N 0.000 description 2
- NPYPAHLBTDXSSS-UHFFFAOYSA-N Potassium ion Chemical compound [K+] NPYPAHLBTDXSSS-UHFFFAOYSA-N 0.000 description 2
- 208000006011 Stroke Diseases 0.000 description 2
- 229930003268 Vitamin C Natural products 0.000 description 2
- 239000002253 acid Substances 0.000 description 2
- 208000026935 allergic disease Diseases 0.000 description 2
- 230000007815 allergy Effects 0.000 description 2
- QVGXLLKOCUKJST-UHFFFAOYSA-N atomic oxygen Chemical compound [O] QVGXLLKOCUKJST-UHFFFAOYSA-N 0.000 description 2
- 230000009286 beneficial effect Effects 0.000 description 2
- 210000000988 bone and bone Anatomy 0.000 description 2
- 235000008429 bread Nutrition 0.000 description 2
- 230000008859 change Effects 0.000 description 2
- 239000003153 chemical reaction reagent Substances 0.000 description 2
- BHQCQFFYRZLCQQ-OELDTZBJSA-N cholic acid Chemical compound C([C@H]1C[C@H]2O)[C@H](O)CC[C@]1(C)[C@@H]1[C@@H]2[C@@H]2CC[C@H]([C@@H](CCC(O)=O)C)[C@@]2(C)[C@@H](O)C1 BHQCQFFYRZLCQQ-OELDTZBJSA-N 0.000 description 2
- 238000002425 crystallisation Methods 0.000 description 2
- 230000008025 crystallization Effects 0.000 description 2
- 238000001514 detection method Methods 0.000 description 2
- 230000035487 diastolic blood pressure Effects 0.000 description 2
- 238000005516 engineering process Methods 0.000 description 2
- 235000011187 glycerol Nutrition 0.000 description 2
- 229910052736 halogen Inorganic materials 0.000 description 2
- 150000002367 halogens Chemical class 0.000 description 2
- 210000002216 heart Anatomy 0.000 description 2
- 229910052739 hydrogen Inorganic materials 0.000 description 2
- 239000001257 hydrogen Substances 0.000 description 2
- 230000001077 hypotensive effect Effects 0.000 description 2
- 238000011835 investigation Methods 0.000 description 2
- 210000003734 kidney Anatomy 0.000 description 2
- JVTAAEKCZFNVCJ-UHFFFAOYSA-N lactic acid Chemical compound CC(O)C(O)=O JVTAAEKCZFNVCJ-UHFFFAOYSA-N 0.000 description 2
- 230000033001 locomotion Effects 0.000 description 2
- 239000011777 magnesium Substances 0.000 description 2
- 229910052749 magnesium Inorganic materials 0.000 description 2
- NCYVXEGFNDZQCU-UHFFFAOYSA-N nikethamide Chemical compound CCN(CC)C(=O)C1=CC=CN=C1 NCYVXEGFNDZQCU-UHFFFAOYSA-N 0.000 description 2
- 230000000050 nutritive effect Effects 0.000 description 2
- 229910052760 oxygen Inorganic materials 0.000 description 2
- 239000001301 oxygen Substances 0.000 description 2
- 210000005259 peripheral blood Anatomy 0.000 description 2
- 239000011886 peripheral blood Substances 0.000 description 2
- 229910001414 potassium ion Inorganic materials 0.000 description 2
- 238000012545 processing Methods 0.000 description 2
- 235000018102 proteins Nutrition 0.000 description 2
- 108090000623 proteins and genes Proteins 0.000 description 2
- 102000004169 proteins and genes Human genes 0.000 description 2
- 230000035485 pulse pressure Effects 0.000 description 2
- 235000021251 pulses Nutrition 0.000 description 2
- 230000001105 regulatory effect Effects 0.000 description 2
- 235000009566 rice Nutrition 0.000 description 2
- 235000015598 salt intake Nutrition 0.000 description 2
- 208000024891 symptom Diseases 0.000 description 2
- 235000019154 vitamin C Nutrition 0.000 description 2
- 239000011718 vitamin C Substances 0.000 description 2
- OILXMJHPFNGGTO-UHFFFAOYSA-N (22E)-(24xi)-24-methylcholesta-5,22-dien-3beta-ol Natural products C1C=C2CC(O)CCC2(C)C2C1C1CCC(C(C)C=CC(C)C(C)C)C1(C)CC2 OILXMJHPFNGGTO-UHFFFAOYSA-N 0.000 description 1
- BHQCQFFYRZLCQQ-UHFFFAOYSA-N (3alpha,5alpha,7alpha,12alpha)-3,7,12-trihydroxy-cholan-24-oic acid Natural products OC1CC2CC(O)CCC2(C)C2C1C1CCC(C(CCC(O)=O)C)C1(C)C(O)C2 BHQCQFFYRZLCQQ-UHFFFAOYSA-N 0.000 description 1
- GDSOZVZXVXTJMI-SNAWJCMRSA-N (e)-1-methylbut-1-ene-1,2,4-tricarboxylic acid Chemical compound OC(=O)C(/C)=C(C(O)=O)\CCC(O)=O GDSOZVZXVXTJMI-SNAWJCMRSA-N 0.000 description 1
- PORPENFLTBBHSG-MGBGTMOVSA-N 1,2-dihexadecanoyl-sn-glycerol-3-phosphate Chemical compound CCCCCCCCCCCCCCCC(=O)OC[C@H](COP(O)(O)=O)OC(=O)CCCCCCCCCCCCCCC PORPENFLTBBHSG-MGBGTMOVSA-N 0.000 description 1
- TZCPCKNHXULUIY-RGULYWFUSA-N 1,2-distearoyl-sn-glycero-3-phosphoserine Chemical compound CCCCCCCCCCCCCCCCCC(=O)OC[C@H](COP(O)(=O)OC[C@H](N)C(O)=O)OC(=O)CCCCCCCCCCCCCCCCC TZCPCKNHXULUIY-RGULYWFUSA-N 0.000 description 1
- OQMZNAMGEHIHNN-UHFFFAOYSA-N 7-Dehydrostigmasterol Natural products C1C(O)CCC2(C)C(CCC3(C(C(C)C=CC(CC)C(C)C)CCC33)C)C3=CC=C21 OQMZNAMGEHIHNN-UHFFFAOYSA-N 0.000 description 1
- ZCYVEMRRCGMTRW-UHFFFAOYSA-N 7553-56-2 Chemical compound [I] ZCYVEMRRCGMTRW-UHFFFAOYSA-N 0.000 description 1
- 206010002065 Anaemia megaloblastic Diseases 0.000 description 1
- 208000006820 Arthralgia Diseases 0.000 description 1
- 235000000832 Ayote Nutrition 0.000 description 1
- 208000012904 Bartter disease Diseases 0.000 description 1
- 208000010062 Bartter syndrome Diseases 0.000 description 1
- 0 CC(C)(CO)[C@](C(N(C)CCC(O*(N(CC1)C([C@@](C(C)(C)CO)O)=O)OC1=O)=O)=O)O Chemical compound CC(C)(CO)[C@](C(N(C)CCC(O*(N(CC1)C([C@@](C(C)(C)CO)O)=O)OC1=O)=O)=O)O 0.000 description 1
- 208000006029 Cardiomegaly Diseases 0.000 description 1
- 208000024172 Cardiovascular disease Diseases 0.000 description 1
- 206010008190 Cerebrovascular accident Diseases 0.000 description 1
- 239000004380 Cholic acid Substances 0.000 description 1
- 208000017667 Chronic Disease Diseases 0.000 description 1
- 235000007516 Chrysanthemum Nutrition 0.000 description 1
- 244000189548 Chrysanthemum x morifolium Species 0.000 description 1
- RYGMFSIKBFXOCR-UHFFFAOYSA-N Copper Chemical compound [Cu] RYGMFSIKBFXOCR-UHFFFAOYSA-N 0.000 description 1
- 235000009917 Crataegus X brevipes Nutrition 0.000 description 1
- 235000013204 Crataegus X haemacarpa Nutrition 0.000 description 1
- 235000009685 Crataegus X maligna Nutrition 0.000 description 1
- 235000009444 Crataegus X rubrocarnea Nutrition 0.000 description 1
- 235000009486 Crataegus bullatus Nutrition 0.000 description 1
- 235000017181 Crataegus chrysocarpa Nutrition 0.000 description 1
- 235000009682 Crataegus limnophila Nutrition 0.000 description 1
- 240000000171 Crataegus monogyna Species 0.000 description 1
- 235000004423 Crataegus monogyna Nutrition 0.000 description 1
- 235000002313 Crataegus paludosa Nutrition 0.000 description 1
- 235000009840 Crataegus x incaedua Nutrition 0.000 description 1
- 206010011469 Crying Diseases 0.000 description 1
- 240000004244 Cucurbita moschata Species 0.000 description 1
- 235000009854 Cucurbita moschata Nutrition 0.000 description 1
- 235000009804 Cucurbita pepo subsp pepo Nutrition 0.000 description 1
- XFXPMWWXUTWYJX-UHFFFAOYSA-N Cyanide Chemical compound N#[C-] XFXPMWWXUTWYJX-UHFFFAOYSA-N 0.000 description 1
- 240000001879 Digitalis lutea Species 0.000 description 1
- 235000002722 Dioscorea batatas Nutrition 0.000 description 1
- 235000006536 Dioscorea esculenta Nutrition 0.000 description 1
- 240000001811 Dioscorea oppositifolia Species 0.000 description 1
- 235000003416 Dioscorea oppositifolia Nutrition 0.000 description 1
- 102000006395 Globulins Human genes 0.000 description 1
- 108010044091 Globulins Proteins 0.000 description 1
- JZNWSCPGTDBMEW-UHFFFAOYSA-N Glycerophosphorylethanolamin Natural products NCCOP(O)(=O)OCC(O)CO JZNWSCPGTDBMEW-UHFFFAOYSA-N 0.000 description 1
- ZWZWYGMENQVNFU-UHFFFAOYSA-N Glycerophosphorylserin Natural products OC(=O)C(N)COP(O)(=O)OCC(O)CO ZWZWYGMENQVNFU-UHFFFAOYSA-N 0.000 description 1
- 206010019280 Heart failures Diseases 0.000 description 1
- 239000009636 Huang Qi Substances 0.000 description 1
- 208000019025 Hypokalemia Diseases 0.000 description 1
- 208000015710 Iron-Deficiency Anemia Diseases 0.000 description 1
- 208000015924 Lithiasis Diseases 0.000 description 1
- 244000241838 Lycium barbarum Species 0.000 description 1
- 235000015459 Lycium barbarum Nutrition 0.000 description 1
- PWHULOQIROXLJO-UHFFFAOYSA-N Manganese Chemical compound [Mn] PWHULOQIROXLJO-UHFFFAOYSA-N 0.000 description 1
- 208000000682 Megaloblastic Anemia Diseases 0.000 description 1
- 241000237536 Mytilus edulis Species 0.000 description 1
- GXCLVBGFBYZDAG-UHFFFAOYSA-N N-[2-(1H-indol-3-yl)ethyl]-N-methylprop-2-en-1-amine Chemical compound CN(CCC1=CNC2=C1C=CC=C2)CC=C GXCLVBGFBYZDAG-UHFFFAOYSA-N 0.000 description 1
- 206010029164 Nephrotic syndrome Diseases 0.000 description 1
- 208000000224 Night Terrors Diseases 0.000 description 1
- 208000001132 Osteoporosis Diseases 0.000 description 1
- 240000004371 Panax ginseng Species 0.000 description 1
- 235000005035 Panax pseudoginseng ssp. pseudoginseng Nutrition 0.000 description 1
- 235000003140 Panax quinquefolius Nutrition 0.000 description 1
- 244000197580 Poria cocos Species 0.000 description 1
- 235000008599 Poria cocos Nutrition 0.000 description 1
- 208000000418 Premature Cardiac Complexes Diseases 0.000 description 1
- 241000288906 Primates Species 0.000 description 1
- 240000001341 Reynoutria japonica Species 0.000 description 1
- 235000018167 Reynoutria japonica Nutrition 0.000 description 1
- 240000007164 Salvia officinalis Species 0.000 description 1
- BUGBHKTXTAQXES-UHFFFAOYSA-N Selenium Chemical compound [Se] BUGBHKTXTAQXES-UHFFFAOYSA-N 0.000 description 1
- 206010041010 Sleep terror Diseases 0.000 description 1
- 108010073771 Soybean Proteins Proteins 0.000 description 1
- 208000005392 Spasm Diseases 0.000 description 1
- 244000228451 Stevia rebaudiana Species 0.000 description 1
- 235000006092 Stevia rebaudiana Nutrition 0.000 description 1
- 241000270666 Testudines Species 0.000 description 1
- HZYXFRGVBOPPNZ-UHFFFAOYSA-N UNPD88870 Natural products C1C=C2CC(O)CCC2(C)C2C1C1CCC(C(C)=CCC(CC)C(C)C)C1(C)CC2 HZYXFRGVBOPPNZ-UHFFFAOYSA-N 0.000 description 1
- 206010047623 Vitamin C deficiency Diseases 0.000 description 1
- 206010047700 Vomiting Diseases 0.000 description 1
- ATBOMIWRCZXYSZ-XZBBILGWSA-N [1-[2,3-dihydroxypropoxy(hydroxy)phosphoryl]oxy-3-hexadecanoyloxypropan-2-yl] (9e,12e)-octadeca-9,12-dienoate Chemical compound CCCCCCCCCCCCCCCC(=O)OCC(COP(O)(=O)OCC(O)CO)OC(=O)CCCCCCC\C=C\C\C=C\CCCCC ATBOMIWRCZXYSZ-XZBBILGWSA-N 0.000 description 1
- WNQQFQRHFNVNSP-UHFFFAOYSA-N [Ca].[Fe] Chemical compound [Ca].[Fe] WNQQFQRHFNVNSP-UHFFFAOYSA-N 0.000 description 1
- 210000004404 adrenal cortex Anatomy 0.000 description 1
- 238000013019 agitation Methods 0.000 description 1
- 150000001336 alkenes Chemical class 0.000 description 1
- AWUCVROLDVIAJX-UHFFFAOYSA-N alpha-glycerophosphate Natural products OCC(O)COP(O)(O)=O AWUCVROLDVIAJX-UHFFFAOYSA-N 0.000 description 1
- 229910000147 aluminium phosphate Inorganic materials 0.000 description 1
- 150000001413 amino acids Chemical class 0.000 description 1
- 239000003674 animal food additive Substances 0.000 description 1
- 239000003963 antioxidant agent Substances 0.000 description 1
- 230000003078 antioxidant effect Effects 0.000 description 1
- 235000006708 antioxidants Nutrition 0.000 description 1
- 230000036528 appetite Effects 0.000 description 1
- 235000019789 appetite Nutrition 0.000 description 1
- 239000011260 aqueous acid Substances 0.000 description 1
- 239000007864 aqueous solution Substances 0.000 description 1
- 206010003119 arrhythmia Diseases 0.000 description 1
- 230000006793 arrhythmia Effects 0.000 description 1
- 230000004872 arterial blood pressure Effects 0.000 description 1
- 235000019606 astringent taste Nutrition 0.000 description 1
- LGJMUZUPVCAVPU-UHFFFAOYSA-N beta-Sitostanol Natural products C1CC2CC(O)CCC2(C)C2C1C1CCC(C(C)CCC(CC)C(C)C)C1(C)CC2 LGJMUZUPVCAVPU-UHFFFAOYSA-N 0.000 description 1
- 235000013361 beverage Nutrition 0.000 description 1
- 210000000941 bile Anatomy 0.000 description 1
- 230000005540 biological transmission Effects 0.000 description 1
- 230000015572 biosynthetic process Effects 0.000 description 1
- 230000004531 blood pressure lowering effect Effects 0.000 description 1
- 210000004204 blood vessel Anatomy 0.000 description 1
- 210000004556 brain Anatomy 0.000 description 1
- 239000000872 buffer Substances 0.000 description 1
- 239000000337 buffer salt Substances 0.000 description 1
- 150000001720 carbohydrates Chemical class 0.000 description 1
- 239000001569 carbon dioxide Substances 0.000 description 1
- 229910002092 carbon dioxide Inorganic materials 0.000 description 1
- 210000002318 cardia Anatomy 0.000 description 1
- 230000000747 cardiac effect Effects 0.000 description 1
- 229940097217 cardiac glycoside Drugs 0.000 description 1
- 239000002368 cardiac glycoside Substances 0.000 description 1
- 210000004027 cell Anatomy 0.000 description 1
- 230000002490 cerebral effect Effects 0.000 description 1
- 208000026106 cerebrovascular disease Diseases 0.000 description 1
- 238000006243 chemical reaction Methods 0.000 description 1
- 238000005660 chlorination reaction Methods 0.000 description 1
- 229940099352 cholate Drugs 0.000 description 1
- 235000019416 cholic acid Nutrition 0.000 description 1
- 229960002471 cholic acid Drugs 0.000 description 1
- 230000001684 chronic effect Effects 0.000 description 1
- 208000035850 clinical syndrome Diseases 0.000 description 1
- 239000005515 coenzyme Substances 0.000 description 1
- 235000009508 confectionery Nutrition 0.000 description 1
- 230000001276 controlling effect Effects 0.000 description 1
- 239000010949 copper Substances 0.000 description 1
- 229910052802 copper Inorganic materials 0.000 description 1
- 208000029078 coronary artery disease Diseases 0.000 description 1
- 239000013078 crystal Substances 0.000 description 1
- 235000013365 dairy product Nutrition 0.000 description 1
- 230000000254 damaging effect Effects 0.000 description 1
- 230000007812 deficiency Effects 0.000 description 1
- 230000002950 deficient Effects 0.000 description 1
- KXGVEGMKQFWNSR-UHFFFAOYSA-N deoxycholic acid Natural products C1CC2CC(O)CCC2(C)C2C1C1CCC(C(CCC(O)=O)C)C1(C)C(O)C2 KXGVEGMKQFWNSR-UHFFFAOYSA-N 0.000 description 1
- 238000011161 development Methods 0.000 description 1
- 206010012601 diabetes mellitus Diseases 0.000 description 1
- 235000015872 dietary supplement Nutrition 0.000 description 1
- 230000029087 digestion Effects 0.000 description 1
- 210000002249 digestive system Anatomy 0.000 description 1
- 238000001035 drying Methods 0.000 description 1
- 235000006694 eating habits Nutrition 0.000 description 1
- 230000002526 effect on cardiovascular system Effects 0.000 description 1
- 239000003792 electrolyte Substances 0.000 description 1
- 235000020774 essential nutrients Nutrition 0.000 description 1
- 230000029142 excretion Effects 0.000 description 1
- 206010016256 fatigue Diseases 0.000 description 1
- 239000000835 fiber Substances 0.000 description 1
- 239000002778 food additive Substances 0.000 description 1
- 238000007710 freezing Methods 0.000 description 1
- 230000008014 freezing Effects 0.000 description 1
- 239000013505 freshwater Substances 0.000 description 1
- 229940029982 garlic powder Drugs 0.000 description 1
- 235000008434 ginseng Nutrition 0.000 description 1
- 150000004676 glycans Chemical class 0.000 description 1
- 125000003745 glyceroyl group Chemical group C(C(O)CO)(=O)* 0.000 description 1
- 208000019622 heart disease Diseases 0.000 description 1
- 208000007475 hemolytic anemia Diseases 0.000 description 1
- 241000411851 herbal medicine Species 0.000 description 1
- 150000002401 hexose derivatives Chemical class 0.000 description 1
- 150000002402 hexoses Chemical class 0.000 description 1
- 206010020718 hyperplasia Diseases 0.000 description 1
- 230000002390 hyperplastic effect Effects 0.000 description 1
- 230000036039 immunity Effects 0.000 description 1
- 238000007689 inspection Methods 0.000 description 1
- PNDPGZBMCMUPRI-UHFFFAOYSA-N iodine Chemical compound II PNDPGZBMCMUPRI-UHFFFAOYSA-N 0.000 description 1
- 239000011630 iodine Substances 0.000 description 1
- 229910052740 iodine Inorganic materials 0.000 description 1
- SURQXAFEQWPFPV-UHFFFAOYSA-L iron(2+) sulfate heptahydrate Chemical compound O.O.O.O.O.O.O.[Fe+2].[O-]S([O-])(=O)=O SURQXAFEQWPFPV-UHFFFAOYSA-L 0.000 description 1
- 239000004310 lactic acid Substances 0.000 description 1
- 235000014655 lactic acid Nutrition 0.000 description 1
- 150000002596 lactones Chemical class 0.000 description 1
- 201000010260 leiomyoma Diseases 0.000 description 1
- 230000003902 lesion Effects 0.000 description 1
- 239000007788 liquid Substances 0.000 description 1
- 210000004185 liver Anatomy 0.000 description 1
- 230000007774 longterm Effects 0.000 description 1
- 210000001699 lower leg Anatomy 0.000 description 1
- 229910001629 magnesium chloride Inorganic materials 0.000 description 1
- 238000010907 mechanical stirring Methods 0.000 description 1
- 231100001016 megaloblastic anemia Toxicity 0.000 description 1
- 230000002969 morbid Effects 0.000 description 1
- 230000004118 muscle contraction Effects 0.000 description 1
- 235000020638 mussel Nutrition 0.000 description 1
- 208000009928 nephrosis Diseases 0.000 description 1
- 231100001027 nephrosis Toxicity 0.000 description 1
- 210000005036 nerve Anatomy 0.000 description 1
- 231100000957 no side effect Toxicity 0.000 description 1
- 231100000252 nontoxic Toxicity 0.000 description 1
- 230000003000 nontoxic effect Effects 0.000 description 1
- 230000001473 noxious effect Effects 0.000 description 1
- 235000015097 nutrients Nutrition 0.000 description 1
- 235000016709 nutrition Nutrition 0.000 description 1
- 230000035764 nutrition Effects 0.000 description 1
- 210000000056 organ Anatomy 0.000 description 1
- 239000003960 organic solvent Substances 0.000 description 1
- 208000005368 osteomalacia Diseases 0.000 description 1
- WTJKGGKOPKCXLL-RRHRGVEJSA-N phosphatidylcholine Chemical compound CCCCCCCCCCCCCCCC(=O)OC[C@H](COP([O-])(=O)OCC[N+](C)(C)C)OC(=O)CCCCCCCC=CCCCCCCCC WTJKGGKOPKCXLL-RRHRGVEJSA-N 0.000 description 1
- 150000008104 phosphatidylethanolamines Chemical class 0.000 description 1
- 229940067626 phosphatidylinositols Drugs 0.000 description 1
- 150000003905 phosphatidylinositols Chemical class 0.000 description 1
- 230000035790 physiological processes and functions Effects 0.000 description 1
- 231100000572 poisoning Toxicity 0.000 description 1
- 230000000607 poisoning effect Effects 0.000 description 1
- 229920001282 polysaccharide Polymers 0.000 description 1
- 239000005017 polysaccharide Substances 0.000 description 1
- 239000002243 precursor Substances 0.000 description 1
- 230000035935 pregnancy Effects 0.000 description 1
- 239000003755 preservative agent Substances 0.000 description 1
- 230000002335 preservative effect Effects 0.000 description 1
- 238000003825 pressing Methods 0.000 description 1
- 230000008569 process Effects 0.000 description 1
- 230000002062 proliferating effect Effects 0.000 description 1
- 230000002035 prolonged effect Effects 0.000 description 1
- 235000015136 pumpkin Nutrition 0.000 description 1
- 238000012372 quality testing Methods 0.000 description 1
- 150000003254 radicals Chemical class 0.000 description 1
- 235000005412 red sage Nutrition 0.000 description 1
- 238000006479 redox reaction Methods 0.000 description 1
- 238000007670 refining Methods 0.000 description 1
- 230000008085 renal dysfunction Effects 0.000 description 1
- 208000007442 rickets Diseases 0.000 description 1
- 208000010233 scurvy Diseases 0.000 description 1
- 230000028327 secretion Effects 0.000 description 1
- 229910052711 selenium Inorganic materials 0.000 description 1
- 239000011669 selenium Substances 0.000 description 1
- 208000026775 severe diarrhea Diseases 0.000 description 1
- 210000000813 small intestine Anatomy 0.000 description 1
- 239000000243 solution Substances 0.000 description 1
- 235000019710 soybean protein Nutrition 0.000 description 1
- 239000003381 stabilizer Substances 0.000 description 1
- 229930002534 steroid glycoside Natural products 0.000 description 1
- 150000008143 steroidal glycosides Chemical class 0.000 description 1
- 229940032091 stigmasterol Drugs 0.000 description 1
- HCXVJBMSMIARIN-PHZDYDNGSA-N stigmasterol Chemical compound C1C=C2C[C@@H](O)CC[C@]2(C)[C@@H]2[C@@H]1[C@@H]1CC[C@H]([C@H](C)/C=C/[C@@H](CC)C(C)C)[C@@]1(C)CC2 HCXVJBMSMIARIN-PHZDYDNGSA-N 0.000 description 1
- BFDNMXAIBMJLBB-UHFFFAOYSA-N stigmasterol Natural products CCC(C=CC(C)C1CCCC2C3CC=C4CC(O)CCC4(C)C3CCC12C)C(C)C BFDNMXAIBMJLBB-UHFFFAOYSA-N 0.000 description 1
- 235000016831 stigmasterol Nutrition 0.000 description 1
- 238000003756 stirring Methods 0.000 description 1
- 239000013589 supplement Substances 0.000 description 1
- 238000003786 synthesis reaction Methods 0.000 description 1
- 230000009885 systemic effect Effects 0.000 description 1
- 230000009967 tasteless effect Effects 0.000 description 1
- 210000001519 tissue Anatomy 0.000 description 1
- 235000015961 tonic Nutrition 0.000 description 1
- 230000001256 tonic effect Effects 0.000 description 1
- 229960000716 tonics Drugs 0.000 description 1
- 231100000331 toxic Toxicity 0.000 description 1
- 231100000167 toxic agent Toxicity 0.000 description 1
- 230000002588 toxic effect Effects 0.000 description 1
- 239000003440 toxic substance Substances 0.000 description 1
- 231100000419 toxicity Toxicity 0.000 description 1
- 230000001988 toxicity Effects 0.000 description 1
- 239000011573 trace mineral Substances 0.000 description 1
- 235000013619 trace mineral Nutrition 0.000 description 1
- 230000007704 transition Effects 0.000 description 1
- 210000002700 urine Anatomy 0.000 description 1
- 230000008673 vomiting Effects 0.000 description 1
- 239000003643 water by type Substances 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23V—INDEXING SCHEME RELATING TO FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES AND LACTIC OR PROPIONIC ACID BACTERIA USED IN FOODSTUFFS OR FOOD PREPARATION
- A23V2002/00—Food compositions, function of food ingredients or processes for food or foodstuffs
Abstract
本发明属于保健品领域,涉及一种富铁保健盐及其制备方法。具体而言,本发明的富铁保健盐包括氯化钠、氯化钾、乳酸亚铁、葡萄糖酸亚铁、硫酸亚铁、黄豆粉、绿豆粉、抗坏血酸、泛酸钙和磷酸钙。该富铁保健盐的制备方法简便易行,所得产品符合低钠调味盐相关标准中的要求,并且能够有效辅助降血压药物来控制高血压患者的血压水平,还具有一定的补血功效,弥补了市场空白,极具经济价值。
Description
技术领域
本发明属于调味品技术领域,涉及一种富铁保健盐及其相应的制备方法。
背景技术
高血压(hypertension)是一种复杂的临床综合征,以体循环动脉血压(收缩压和/或舒张压)增高作为主要特征(收缩压≥140mmHg,舒张压≥90mmHg),可伴有心、脑、肾等器官的功能性或器质性损害。高血压是目前最常见的慢性病,也是心脑血管病最主要的危险因素。
多项研究表明,盐的摄入量与血压水平呈正比,即人体摄盐量越多则血压水平越高,日均摄盐量每增加1克,平均血压上升2mmHg。我国高血压的发病率呈现出北高南低之势,这与南甜北咸的饮食习惯密切相关,也从侧面表明了盐与高血压的关系。众所周知,食盐的主要成分是氯化钠(sodium chloride,NaCl),但人体对于钠的生理需要量实际上是很低的,成人每天大约需要3~5g氯化钠,若摄取过多可造成体内水潴留,血管内压力升高,阻力增大,使心脏负荷加重,久而久之会造成心脏肥大、心衰、肾功能异常等难以治愈的疾病。由此可见,限盐(尤其是限钠)绝对有益于高血压患者。
贫血是一种常见的临床症状,具体是指人体外周血的红细胞容量减少,低于正常范围的下限。由于红细胞容量的测定比较复杂,因此临床上常以血红蛋白(Hb)浓度来代替。1972年WHO制订的诊断标准认为:在海平面地区Hb低于下述水平即可诊断为贫血:6个月~6岁儿童110g/L,6~14岁儿童120g/L,成年男性130g/L,成年女性120g/L,孕妇110g/L。基于不同的临床特点,贫血有不同的分类。按照骨髓红细胞系统增生情况可分为增生性贫血(如溶血性贫血、缺铁性贫血、巨幼细胞贫血等)和增生低下性贫血(如再生障碍性贫血),其中最常见的是缺铁性贫血。
作为人体必需的微量元素之一,铁(iron,Fe)是合成血红蛋白(在人体内发挥输送氧气和二氧化碳的作用)的主要成分。如果人体对铁的摄入量不足,便会影响到血红蛋白的合成,从而使红细胞中血红蛋白的含量显著减少,红细胞数目也会随之减少,进而使人体内的细胞、组织、器官等供氧不足,导致缺铁性贫血并影响机体的免疫力。
CN 1099944 A公开了一种平衡保健盐,其包括食用精盐、食用氯化钾和卤盐(卤盐包含55±5%的氯化钠、6.5±1.5%的氯化钾、15±3%的氯化镁以及铁、锌、铜、锰等微量元素),但实施例中具体公开的产品配方中食用精盐(氯化钠)的含量仍然较高(重量百分比为68%),不符合中华人民共和国轻工行业标准《QB/T 2020-2016调味盐》中关于低钠调味盐的要求;CN 1104867 A中公开的多元保健盐、CN 1461603 A中公开的维生素、多元素营养盐以及CN 106174402 A中公开的全营养元素保健盐也存在类似问题。CN 101518325 A公开了一种食用保健盐,其包括食盐和硫酸亚铁(500~600:1~20),但其中的食盐并不是低钠盐,并且存在铁剂用量少、品种单一的问题。CN 1107666 A公开了一种保健盐,其包括钠钾碘盐(钠钾比例为2:1)、微量元素(锌、钙、铁、磷、镁、硒)、维生素(VA、VC、VE、VB1、VB2、VB6、β-胡萝卜素、SOD、DHA)和中草药类(人参、麦芽、山楂、陈皮、桅子、丹参、枸杞、茯苓、黄芪、菊花、白术、山药、酸枣仁、何首乌、甜叶菊、鳖甲粉、牡蛎粉、蚌粉、蚂蚁粉、南瓜粉、蒜粉等),但所使用的钠钾碘盐中氯化钠的含量仍然较高(重量百分比约为61%),铁素的含量较低,并且组成配方的组分繁多,可操作性不强。
发明内容
本发明的目的在于提供一种氯化钠含量符合低钠调味盐标准并且具有辅助调节血压和补血功效的富铁保健盐及其制备方法,以弥补市场的空白。
为了实现上述目的,本发明采用如下技术方案:
一种富铁保健盐,其包括氯化钠、氯化钾、乳酸亚铁、葡萄糖酸亚铁、硫酸亚铁、黄豆粉、绿豆粉、抗坏血酸、泛酸钙和磷酸钙。
以重量百分比计,上述富铁保健盐包括40%~50%的氯化钠、10%~30%的氯化钾、2%~5%的乳酸亚铁、5%~8%的葡萄糖酸亚铁、2%~5%的硫酸亚铁、3%~8%的黄豆粉、2%~6%的绿豆粉、2%~5%的抗坏血酸、1%~2%的泛酸钙和1%~2%的磷酸钙,各组分的重量百分比之和为100%。
优选的,以重量百分比计,上述富铁保健盐包括50%的氯化钠、25%的氯化钾、3%的乳酸亚铁、5%的葡萄糖酸亚铁、2%的硫酸亚铁、6%的黄豆粉、4%的绿豆粉、3%的抗坏血酸、1%的泛酸钙和1%的磷酸钙。
氯化钾(potassium chloride,KCl)是临床常用的电解质平衡调节药,临床疗效确切,广泛用于临床各科,用于治疗和预防各种原因(进食不足、呕吐、严重腹泻、应用排钾利尿药、长期应用糖皮质刺激素和肾上腺皮质刺激素、失钾性肾病、巴特氏综合征等)引起的低钾血症,亦可用于心、肾性水肿以及洋地黄等强心苷中毒引起的频发性、多源性早搏或快速心律失常。通过向食盐中加入氯化钾可以降低氯化钠的相对含量,进而降低高血压的发生率,其原因在于:一方面,钾离子可以抑制肾对钠离子的二次吸收,促进尿钠的排泄;另一方面,钾离子可以对抗钠离子对血管的损伤作用。然而,仅靠限盐补钾并不能完全应对高血压,因为单一的补钾排钠并不能提高人体的自我调节能力,倘若血压控制不好,忽高忽低,反而会诱发冠心病、脑卒中等疾病,因此还需要搭配使用其他活性成分来提高人体自身的血压调控能力。
乳酸亚铁(ferrous lactate,Fe(C3H5O3)2),为常用的铁质强化剂,也是治疗贫血的矿物类非处方药物。乳酸亚铁溶于水后形成带绿色的透明液体,呈酸性,几乎不溶于乙醇。乳酸亚铁的吸收效果比无机铁好,广泛应用于食品、饮料、乳制品、食盐、营养液、药品等。
葡萄糖酸亚铁(ferrous gluconate,Fe(C6H11O7)2),在食品中可用作护色剂、营养强化剂,与乳酸亚铁一样同为有机酸盐类补铁剂。葡萄糖酸亚铁的特点是水溶性好,易吸收,生物利用率高,对消化系统无刺激、无副作用,风味平和、无涩味,对食品的感官性能和风味几乎没有影响。
硫酸亚铁(ferrous sulfate,FeSO4),无结晶水时为白色粉末,含结晶水时为浅绿色晶体(俗称“绿矾”),溶于水、甘油,不溶于乙醇。硫酸亚铁在医药上可用于治疗缺铁性贫血症,还可以作为局部收敛剂及补血剂,用于子宫肌瘤引起的慢性失血。
黄豆粉是指黄豆(又称大豆,豆科大豆属植物大豆Glycine max(Linn.)Merr.的种子)炒过后磨制而成的粉末。黄豆粉比黄豆更容易消化,从而使黄豆中的食物纤维、蛋白质及氨基酸能够被更好地吸收。黄豆粉中的大豆蛋白质和豆固醇还能够明显地改善和降低血脂和胆固醇,从而降低患心血管疾病的概率。另外,黄豆粉还含有钙、镁、钾、磷等人体必需的矿物质。
绿豆粉是指绿豆(豆科豇豆属植物绿豆Vigna radiata(Linn.)Wilczek.的种子)经水磨加工而得的粉末。绿豆粉含有丰富无机盐和维生素,可以为处于高温环境中的人体及时补充丢失的营养物质,达到清热解暑的效果。绿豆粉中的磷脂类成分(如磷脂酰胆碱、磷脂酰乙醇胺、磷脂酰肌醇、磷脂酰甘油、磷脂酰丝氨酸和磷脂酸)具有增进食欲作用。绿豆粉中还含有球蛋白和多糖,能够促进胆固醇在肝脏中分解成胆酸,加速胆汁中胆盐的分泌,并降低小肠对胆固醇的吸收,极具保健价值。
抗坏血酸(ascorbic acid),又称维生素C(vitamin C,VC),为酸性己糖衍生物(烯醇式己糖酸内酯),易溶于水,不溶于有机溶剂,是高等灵长类动物的必需营养素。抗坏血酸在大多数生物体中可以通过新陈代谢而获得,但人类是最显著的例外,人体缺乏抗坏血酸将会造成坏血病。在生物体内,抗坏血酸是一种抗氧化剂,保护身体免于自由基的威胁;同时,抗坏血酸还是一种辅酶,广泛参与生物体内的多种氧化还原反应。此外,抗坏血酸的摄入量不足还会影响生物体对于铁、锌等矿物质的吸收。
钙是人体生命活动所必需的元素,是机体新陈代谢的源泉,人的生命活动如神经物质的传递、心脏搏动、肌肉收缩等都在利用和消耗钙元素。钙在体内主要存在于骨骼和牙齿中(约占99%),支持人体的运动和咀嚼能力。另外,血液中也溶解有一定量的钙,正常人的血钙水平维持在2.18-2.63mmol/L(9-11mg/dl)的范围内,如果低于这个范围,则认定为缺钙。长期缺钙将会引发下列症状:(1)儿童:夜惊、夜啼、烦躁、“X”形腿、“O”形腿、佝偻病、骨骼发育不良等;(2)青少年:抽筋、疲倦乏力、精力不集中、易感冒、易过敏等;(3)青壮年:经常性的倦怠、乏力、抽筋、腰酸背疼、易感冒、易过敏等;(4)孕产妇:小腿痉挛、腰酸腿疼、关节疼痛、浮肿、妊娠高血压等;(5)中老年人:腰酸腿软无力、骨质疏松、骨质软化、各类骨折及结石症、糖尿病、高血压、心脏病等。另外,如上所述,某些有机酸盐型补锌药的使用也会影响人体对钙的吸收利用,使缺钙状况加重。因此,选择合适的钙强化剂至关重要。
泛酸钙(calcium pantothenate),易溶于水和甘油,不溶于酒精、氯仿和乙醚,主要用于医药、食品及饲料添加剂。泛酸钙是合成辅酶A的重要前体,参与碳水化合物、脂肪和蛋白质的代谢,是维持正常生理机能不可缺少的微量物质。
抗结剂(又称抗结块剂)是一类用于防止食盐颗粒或粉状聚集结块,保持其松散或自由流动的试剂,其化学性质独特、稳定,几无毒、无味,易溶于水,颗粒细微,松散多孔,对水分的吸附力强,进而持久且稳定地使食盐保持颗粒或粉末状态。亚铁氰化钾具有抗结性能,可用于防止细粉、结晶性食品发生板结。例如,食盐长久堆放易发生板结,加入亚铁氰化钾后,食盐的正六面体结晶转变为星状结晶,从而不易发生结块。虽然亚铁氰化钾自身毒性很低,但其水溶液与酸反应或者将其加热都会生成极毒的氰化物。相比而言,同样可以用作抗结剂的磷酸钙(calcium phosphate)则不会产生剧毒物质,同时还可以用作缓冲剂(磷酸缓冲盐)和营养增补剂(提供磷元素和钙元素),一举多得。
上述富铁保健盐的制备方法,其包括如下步骤:
1)精制无机盐:将配方量的氯化钠、氯化钾、乳酸亚铁、葡萄糖酸亚铁和硫酸亚铁加入到适量的小分子团水中,于室温混合均匀后进行真空冷冻干燥,得到无机盐精制品;
2)混合物料:将配方量的黄豆粉、绿豆粉、抗坏血酸和泛酸钙与步骤1)中得到的无机盐精制品于室温混合均匀,加入配方量的磷酸钙后再次于室温混合均匀,得到富铁保健盐。
由10个以上的水分子通过氢键缔结形成水团簇的水通常称为大分子团水,而上述制备方法中使用的小分子团水中的水团簇只包含5至6个水分子。通过包括去离子、超声、磁化等处理步骤的方法可以改变水分子的排列取向,切断部分氢键,进而得到团簇较小的小分子团水。
与现有技术相比,采用上述技术方案的本发明具有下列优点:
1)现有技术中缺乏符合调味盐相关要求的富铁保健盐产品,本发明恰恰弥补了上述空白;
2)综合利用乳酸亚铁、葡萄糖酸亚铁和硫酸亚铁来发挥补铁补血的功效,同时补加泛酸钙来避免有机酸盐型补铁剂带来的补铁抑钙现象,实现了钙铁同补;
3)利用黄豆粉和绿豆粉的增鲜作用,优化了调味盐的风味,改善了食品的口感;
4)加入抗坏血酸作为防腐剂,保证了组合物的稳定性,同时作为VC补充剂,有利于铁元素在体内的吸收;
5)加入作为抗结剂的磷酸钙,避免了亚铁氰化钾的使用,降低了产生有毒物质的风险;
6)实验证明,本发明的富铁保健盐能够有效辅助降血压药物来调节血压,并且具有一定的补血功效,制法简便易行,极具市场前景。
具体实施方式
下面将结合具体实施例对本发明的技术方案做出进一步的阐述。下列实施例仅用于解释和说明本发明,并不应被视为限制了本发明的范围。除另有说明外,下列实施例中所使用的仪器、试剂、材料等均可通过常规商业手段获得。
实施例1:小分子团水的制备。
将自来水通入去离子设备中进行去离子化处理,直至电导率为15μs/cm,得到去离子水并量取1L备用。选用频率为30kHz的超声波功率仪,首先设定磁感应强度为0.5T的恒定磁场,超声加磁场作用5min,其次设定磁感应强度为1T的恒定磁场,超声加磁场作用10min,最后设定磁感应强度为0.75T的恒定磁场,超声加磁场作用15min,静置至室温后进行17O-NMR测定。经过上述处理,水的半峰宽从原来的122.74Hz降至50.47Hz,由此可知,所得产品中水分子的团簇数由11变为5;静置14天后,半峰宽变为52.74Hz,产品中水分子的团簇数仍为5,稳定性良好。
实施例2-实施例6:富铁保健盐的制备。
按照表1中的配方制备富铁保健盐,其制备工艺如下:将氯化钠、氯化钾、乳酸亚铁、葡萄糖酸亚铁和硫酸亚铁加入到200mL小分子团水中,利用机械搅拌装置将上述混合物于室温搅拌均匀,然后利用真空冷冻干燥装置进行冻干,得到无机盐精制品;再利用机械搅拌装置将黄豆粉、绿豆粉、抗坏血酸和泛酸钙与上述无机盐精制品于室温混合均匀,加入磷酸钙后再次于室温混合均匀,得到富铁保健盐。
表1.富铁保健盐的处方及用量
实施例7:富铁保健盐的质量检测。
按照《QB/T 2020-2016调味盐》中的检测项目及检测方法对实施例2~6中的富铁保健盐进行检测,其结果如表2所示。由表2可知,各项指标均符合标准要求。
表2.富铁保健盐的质检结果
实施例8:富铁保健盐的辅助降血压作用。
对实施例6中的富铁保健盐进行降血压作用考察。选取高血压患者90人(收缩压>180mmHg,脉压差>60mmHg),共分三组,每组30人,随机分组,男女各半(男性均为60岁以上,女性均为55岁以上)。第I组和第II组患者在服用降血压药物期间同时服用富铁保健盐,以替代普通食盐,每日于午餐及晚餐时各取富铁保健盐3g佐餐,第I组连续使用4周,第II组连续使用2周。第III组为对照组,患者在服用降血压药物期间同时服用普通食盐,连续使用4周。各组的治疗结果如表3所示。
表3.富铁保健盐的降血压作用
由表3可知,与“普通食盐+降血压药物”的组合相比,使用本发明的富铁保健盐来配合降血压药物能够显著降低收缩压及脉压差,并且连续使用4周的效果要优于连续使用2周的效果,坚持使用本发明的富铁保健盐可以逐步降低人体对于钠离子的摄入量,同时保留食物鲜美的风味和口感,有益于配合降血压药物来控制高血压患者的血压水平。
实施例9:富铁保健盐的补铁补血作用。
对实施例6中的富铁保健盐进行补血作用考察。选取缺铁性贫血患者30人(Hb<120g/L),均为45岁以上的女性,共分三组,每组10人。第I组和第II组患者服用富铁保健盐来替代普通食盐,每日于午餐及晚餐时各取富铁保健盐3g佐餐,第I组连续使用4周,第II组连续使用2周。第III组为对照组,患者服用普通食盐,连续使用4周。各组的治疗结果如表4所示。
表4.富铁保健盐的补血作用
由表4可知,与对照组相比,使用本发明的富铁保健盐能够显著提高缺铁性贫血患者的外周血Hb浓度,实现补铁补血的功效。
Claims (6)
1.一种富铁保健盐,其包括氯化钠、氯化钾、乳酸亚铁、葡萄糖酸亚铁、硫酸亚铁、黄豆粉、绿豆粉、抗坏血酸、泛酸钙和磷酸钙。
2.根据权利要求1所述的富铁保健盐,其特征在于:
以重量百分比计,所述富铁保健盐包括40%~50%的氯化钠、10%~30%的氯化钾、2%~5%的乳酸亚铁、5%~8%的葡萄糖酸亚铁、2%~5%的硫酸亚铁、3%~8%的黄豆粉、2%~6%的绿豆粉、2%~5%的抗坏血酸、1%~2%的泛酸钙和1%~2%的磷酸钙,各组分的重量百分比之和为100%。
3.根据权利要求2所述的富铁保健盐,其特征在于:
以重量百分比计,所述富铁保健盐包括50%的氯化钠、25%的氯化钾、3%的乳酸亚铁、5%的葡萄糖酸亚铁、2%的硫酸亚铁、6%的黄豆粉、4%的绿豆粉、3%的抗坏血酸、1%的泛酸钙和1%的磷酸钙。
4.一种根据权利要求1至3中任一项所述的富铁保健盐的制备方法,其包括如下步骤:
1)精制无机盐:将配方量的氯化钠、氯化钾、乳酸亚铁、葡萄糖酸亚铁和硫酸亚铁加入到适量的小分子团水中,于室温混合均匀后进行真空冷冻干燥,得到无机盐精制品;
2)混合物料:将配方量的黄豆粉、绿豆粉、抗坏血酸和泛酸钙与步骤1)中得到的无机盐精制品于室温混合均匀,加入配方量的磷酸钙后再次于室温混合均匀,得到富铁保健盐。
5.根据权利要求4所述的制备方法,其特征在于:
所述小分子团水通过包括去离子、超声、磁化步骤的方法制得。
6.根据权利要求4所述的制备方法,其特征在于:
所述小分子团水中的水团簇包含5至6个水分子。
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN201710255873.0A CN107028149A (zh) | 2017-04-19 | 2017-04-19 | 一种富铁保健盐及其制备方法 |
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN201710255873.0A CN107028149A (zh) | 2017-04-19 | 2017-04-19 | 一种富铁保健盐及其制备方法 |
Publications (1)
Publication Number | Publication Date |
---|---|
CN107028149A true CN107028149A (zh) | 2017-08-11 |
Family
ID=59535899
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CN201710255873.0A Pending CN107028149A (zh) | 2017-04-19 | 2017-04-19 | 一种富铁保健盐及其制备方法 |
Country Status (1)
Country | Link |
---|---|
CN (1) | CN107028149A (zh) |
Cited By (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN109998084A (zh) * | 2019-05-21 | 2019-07-12 | 重庆康春福健康科技有限公司 | 一种限钠咸味素 |
CN110226732A (zh) * | 2019-06-06 | 2019-09-13 | 益盐堂(应城)健康盐制盐有限公司 | 一种具有缓解用眼疲劳作用的调味盐及其制备方法 |
CN111227217A (zh) * | 2020-02-26 | 2020-06-05 | 福建师范大学泉港石化研究院 | 一种低钠补血碘盐及其制备方法 |
Citations (5)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN1073841A (zh) * | 1992-12-11 | 1993-07-07 | 聂景民 | 营养保健复合盐及其制备方法 |
CN1107666A (zh) * | 1994-03-17 | 1995-09-06 | 王跃进 | 保健盐 |
CN102240026A (zh) * | 2010-05-14 | 2011-11-16 | 张丕营 | 多功能营养盐 |
CN106174402A (zh) * | 2016-07-20 | 2016-12-07 | 李新民 | 一种全营养元素保健盐及其制备方法 |
CN106473149A (zh) * | 2015-08-25 | 2017-03-08 | 广州硕维食品技术有限公司 | 一种多维多矿组合物 |
-
2017
- 2017-04-19 CN CN201710255873.0A patent/CN107028149A/zh active Pending
Patent Citations (5)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN1073841A (zh) * | 1992-12-11 | 1993-07-07 | 聂景民 | 营养保健复合盐及其制备方法 |
CN1107666A (zh) * | 1994-03-17 | 1995-09-06 | 王跃进 | 保健盐 |
CN102240026A (zh) * | 2010-05-14 | 2011-11-16 | 张丕营 | 多功能营养盐 |
CN106473149A (zh) * | 2015-08-25 | 2017-03-08 | 广州硕维食品技术有限公司 | 一种多维多矿组合物 |
CN106174402A (zh) * | 2016-07-20 | 2016-12-07 | 李新民 | 一种全营养元素保健盐及其制备方法 |
Non-Patent Citations (1)
Title |
---|
高雪丽: "《食品添加剂》", 31 January 2013, 中国科学技术出版社 * |
Cited By (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN109998084A (zh) * | 2019-05-21 | 2019-07-12 | 重庆康春福健康科技有限公司 | 一种限钠咸味素 |
CN110226732A (zh) * | 2019-06-06 | 2019-09-13 | 益盐堂(应城)健康盐制盐有限公司 | 一种具有缓解用眼疲劳作用的调味盐及其制备方法 |
CN111227217A (zh) * | 2020-02-26 | 2020-06-05 | 福建师范大学泉港石化研究院 | 一种低钠补血碘盐及其制备方法 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
CN101731514B (zh) | 系列营养小米粉复合物 | |
CN102742837B (zh) | 一种用于改善营养不良症状的保健食品及其制备方法 | |
CN101049150B (zh) | 有广泛用途的食用营养保健钾盐 | |
CN106213495A (zh) | 减肥型代餐粉及其制备方法 | |
CN105410904B (zh) | 适用于幼儿补钙的乳酸钙颗粒组合物 | |
CN103211162A (zh) | 一种经发酵处理的杂粮食品及其制备方法 | |
CN102106393B (zh) | 一种富含纤维素的乳制品及其制备方法 | |
CN103039615A (zh) | 一种五谷杂豆豆奶粉及其制备方法 | |
CN107028149A (zh) | 一种富铁保健盐及其制备方法 | |
CN108522969A (zh) | 一种可降血糖的复方营养粉剂 | |
CN107048329A (zh) | 一种富锌保健盐及其制备方法 | |
CN102428985A (zh) | 红枣保健预拌粉 | |
CN104397576A (zh) | 一种超微黑木耳粉营养强化粥及其制备方法 | |
CN107495053A (zh) | 一种复合型高钙蛋白粉制剂的制备方法 | |
KR20010084126A (ko) | 면의 제조방법 | |
CN103461536B (zh) | 一种补钙保健米糠油 | |
CN107183400A (zh) | 一种蛋鸡饲料 | |
CN106858523A (zh) | 一种低钠调味盐及其制备方法 | |
CN101623100B (zh) | 一种利用流化床喷涂技术生产营养强化米的方法 | |
CN1401758A (zh) | 一种制备食疗保健醋的方法及用该方法生产的食疗保健醋 | |
KR100336650B1 (ko) | 두뇌 활성화 및 성장 촉진 기능을 강화한 생식 타입의차(茶) 조성물 | |
KR100325584B1 (ko) | 항당뇨 기능의 생식 타입 차(茶) 조성물 | |
CN103622090A (zh) | 一种能强肾健体的新型粉糊 | |
CN102972529A (zh) | 槐花蜜豆浆及其制备方法 | |
CN103798596B (zh) | 一种供心脑血管疾病患者食用的全营养配方食品 |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
PB01 | Publication | ||
PB01 | Publication | ||
SE01 | Entry into force of request for substantive examination | ||
SE01 | Entry into force of request for substantive examination | ||
RJ01 | Rejection of invention patent application after publication | ||
RJ01 | Rejection of invention patent application after publication |
Application publication date: 20170811 |